Évaluation de la suspension inhalée TQC3721 chez les patients atteints de bronchopneumopathie chronique obstructive modérée à sévère
Évaluation du profil de sécurité dans une étude de cohorte de la suspension inhalée de TQC3721 chez des patients atteints de bronchopneumopathie chronique obstructive modérée à sévère
To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Weimin Li, Doctor
- Numéro de téléphone: 028-85423998
- E-mail: weimin003@163.com
Lieux d'étude
-
-
Anhui
-
Chizhou, Anhui, Chine, 247000
- Recrutement
- Chizhou People's Hospital
-
Contact:
- Yuping Wei, Master
- Numéro de téléphone: 15339668463
- E-mail: weiyuping@sina.com
-
Hefei, Anhui, Chine, 238000
- Recrutement
- Chaohu Hospital of Anhui Medical University
-
Contact:
- Fanliang Meng, Master
- Numéro de téléphone: 13966337677
- E-mail: 13966337677@163.com
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Chine, 404000
- Recrutement
- Chongqing University Three Gorges Hospital
-
Contact:
- Liangping Mao, Master
- Numéro de téléphone: 13709436633
- E-mail: 13709436633@163.com
-
Chongqing, Chongqing Municipality, Chine, 400054
- Recrutement
- Peolpe's Hospital Of Chongqing Banan District
-
Contact:
- Tiefeng Zhang, Doctor
- Numéro de téléphone: 13816503538
- E-mail: zhangtief@hotmail.com
-
Chongqing, Chongqing Municipality, Chine, 408099
- Recrutement
- Fuling Hospital Affiliated to Chongqing University
-
Contact:
- Qianli Ma, Doctor
- Numéro de téléphone: 13996030312
- E-mail: cqmql@163.com
-
-
Fujian
-
Zhangzhou, Fujian, Chine, 363000
- Recrutement
- Zhangzhou Municipal Hospital of Fujian Province
-
Contact:
- Li Lin, Bachelor
- Numéro de téléphone: 13605080222
- E-mail: linlid222@163.com
-
-
Gansu
-
Lanzhou, Gansu, Chine, 730000
- Recrutement
- The First Hospital of Lanzhou University
-
Contact:
- Xiaoju Liu, Doctor
- Numéro de téléphone: 13919360884
- E-mail: Liuxiaoju835@126.com
-
Lanzhou, Gansu, Chine, 730099
- Recrutement
- Gansu Provincial Hospital
-
Contact:
- Weidong Hu, Bachelor
- Numéro de téléphone: 13519311855
- E-mail: weidong-618@163.com
-
Contact:
- Linxia Fan, Master
- Numéro de téléphone: 13609311774
- E-mail: fanlinxia6@163.com
-
-
Guangdong
-
Foshan, Guangdong, Chine, 528300
- Recrutement
- The Eighth Affiliated Hospital of Southern Medical University (The First people's Hospital of Shunde )
-
Contact:
- Yanhua Lv, Doctor
- Numéro de téléphone: 18923332273
- E-mail: lyhshunde@163.com
-
Shenzhen, Guangdong, Chine, 518000
- Recrutement
- Peking University Shenzhen Hospital
-
Contact:
- Zhongdong lv, Doctor
- Numéro de téléphone: 13825167802
- E-mail: sunruilin213@126.com
-
-
Guizhou
-
Guiyang, Guizhou, Chine, 550000
- Recrutement
- Guizhou Provincial People's Hospital
-
Contact:
- Xianwei Ye, Doctor
- Numéro de téléphone: 18798619198
- E-mail: yxw1205@163.com
-
-
Hainan
-
Haikou, Hainan, Chine, 570102
- Recrutement
- The First Affiliated Hospital of Hainan Medical University
-
Contact:
- Huaping Huang, Doctor
- Numéro de téléphone: 13138997957
- E-mail: 1297034257@qq.com
-
-
Hebei
-
Langfang, Hebei, Chine, 65000
- Recrutement
- Hebei PetroChina Central Hospital
-
Contact:
- Zheng Liu, Master
- Numéro de téléphone: 186 3261 9559
- E-mail: keaiduo68@163.com
-
Xingtai, Hebei, Chine, 054000
- Recrutement
- People Hospital of Xingtai
-
Contact:
- Zhiguo Gao, Master
- Numéro de téléphone: 13482950466
- E-mail: gaozhiguohao@126.com
-
-
Heilongjiang
-
Daqing, Heilongjiang, Chine, 163000
- Recrutement
- Daqing Longnan Hospital
-
Contact:
- Jinli Liu, Bachelor
- Numéro de téléphone: 18845980808
- E-mail: 969089802@qq.com
-
Qiqihar, Heilongjiang, Chine, 161005
- Recrutement
- Qiqihar First Hospital
-
Contact:
- Jian Ding, Master
- Numéro de téléphone: 15645231111
- E-mail: 252518789@qq.com
-
-
Henan
-
Jiaozuo, Henan, Chine, 454001
- Recrutement
- Jiaozuo Second People's Hospital
-
Contact:
- Xinju Xu, Bachelor
- Numéro de téléphone: 13569183612
- E-mail: 13569183612@163.com
-
Puyang, Henan, Chine, 457001
- Recrutement
- Puyang Oilfield General Hospital
-
Contact:
- Faming Yu, Bachelor
- Numéro de téléphone: 13700802698
- E-mail: mingfayu@126.com
-
Shangqiu, Henan, Chine, 476100
- Recrutement
- The First People's Hospital of Shangqiu
-
Contact:
- Chunling Zhang, Master
- Numéro de téléphone: 13781626918
- E-mail: chunlingz@yeah.net
-
-
Hubei
-
Yichang, Hubei, Chine, 443003
- Recrutement
- Yichang Central People's Hospital
-
Contact:
- Fanjun Zeng, Master
- Numéro de téléphone: 13997672619
- E-mail: 438864941@qq.com
-
-
Hunan
-
Changsha, Hunan, Chine, 410001
- Recrutement
- Hunan Provincial People's Hospital
-
Contact:
- Nian Liu, Master
- Numéro de téléphone: 13975188303
- E-mail: 19781138@qq.com
-
Yongzhou, Hunan, Chine, 425002
- Recrutement
- The Central Hospital of Yongzhou
-
Contact:
- Ni Zhang, Bachelor
- Numéro de téléphone: 15200973322
- E-mail: 1335614905@qq.com
-
-
Inner Mongolia
-
Chifeng, Inner Mongolia, Chine, 24000
- Recrutement
- Chifeng Municipal Hospital
-
Contact:
- Xiaohua Li, Master
- Numéro de téléphone: 18047660682
- E-mail: lixiaohuaaa@aliyun.com
-
-
Jiangsu
-
Wuxi, Jiangsu, Chine, 214001
- Recrutement
- The Fifth People's Hospital of Wuxi
-
Contact:
- Feng Zhu, Doctor
- Numéro de téléphone: 13914135026
- E-mail: 181515688@qq.com
-
Wuxi, Jiangsu, Chine, 214400
- Recrutement
- Jiangyin Hospital of Traditional Chinese Medicine
-
Contact:
- Xiaodong Hu, Bachelor
- Numéro de téléphone: 17768318018
- E-mail: 30223273@qq.com
-
Xuzhou, Jiangsu, Chine, 221009
- Pas encore de recrutement
- Xuzhou Central Hospital
-
Contact:
- Yanmin Wu, Master
- Numéro de téléphone: 18952170625
- E-mail: wymin666@163.com
-
Yangzhou, Jiangsu, Chine, 225001
- Recrutement
- Subei People's Hospital of Jiangsu province
-
Contact:
- Lingfeng Min, Doctor
- Numéro de téléphone: 18051061783
- E-mail: minlingfeng@126.com
-
Yixing, Jiangsu, Chine, 225000
- Recrutement
- Yixing People's Hospital
-
Contact:
- Jianzhong Jiang, Bachelor
- Numéro de téléphone: 15906156662
- E-mail: staff290@yxph.com
-
Contact:
- Xiuqin Ma, Master
- Numéro de téléphone: 13815117833
- E-mail: staff799@yxph.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Chine, 330006
- Recrutement
- The First Affiliated Hospital of Nanchang University
-
Contact:
- Wei Zuo, Master
- Numéro de téléphone: 15879098337
- E-mail: 11545394@qq.com
-
Nanchang, Jiangxi, Chine, 330006
- Recrutement
- Jiangxi Provincial People's Hospital
-
Contact:
- Zuke Xiao, Bachelor
- Numéro de téléphone: 13970010036
- E-mail: Xiaozuke@126.com
-
-
Jilin
-
Changchun, Jilin, Chine, 130000
- Recrutement
- The first hospital of Jilin University
-
Contact:
- Liping Peng, Doctor
- Numéro de téléphone: 13756661263
- E-mail: plp640317@163.com
-
-
Liaoning
-
Dalian, Liaoning, Chine, 116000
- Recrutement
- Central Hospital of Dalian University of Technology
-
Contact:
- Jian Xu, Doctor
- Numéro de téléphone: 15509850880
- E-mail: karlinee@163.com
-
Shenyang, Liaoning, Chine, 110021
- Recrutement
- Shengjing Hospital of China Medical University
-
Contact:
- Rui Zheng, Master
- Numéro de téléphone: 18940002266
- E-mail: zhengr@sj-hospital.org
-
-
Neimenggu
-
Hohhot, Neimenggu, Chine, 10000
- Recrutement
- Inner Mongolia Medical University Affiliated Hospital
-
Contact:
- Lihong Wang, Master
- Numéro de téléphone: 13848137292
- E-mail: 1152329174@qq.com
-
-
Shandong
-
Binzhou, Shandong, Chine, 256610
- Recrutement
- Binzhou People's Hospital
-
Contact:
- KaiShu Li, Doctor
- Numéro de téléphone: 15954318626
- E-mail: 15954318626@163.com
-
Heze, Shandong, Chine, 274031
- Recrutement
- Heze Municipal Hospital
-
Contact:
- Xunchao Liu, Doctor
- Numéro de téléphone: 13184069557
- E-mail: lxunchao@163.com
-
Jining, Shandong, Chine, 272029
- Recrutement
- Affiliated Hospital of Jining Medical University
-
Contact:
- Bo Jiang, Master
- Numéro de téléphone: 15666752870
- E-mail: 13793771252@163.com
-
Weifang, Shandong, Chine, 261000
- Recrutement
- Weifang NO.2 People's Hospital
-
Contact:
- Guoru Yang, Bachelor
- Numéro de téléphone: 13963601993
- E-mail: yangguoru@163.com
-
Yantai, Shandong, Chine, 264099
- Recrutement
- Yantai Yuhuangding Hospital
-
Contact:
- Shenchun Zhou, Master
- Numéro de téléphone: 18660515179
- E-mail: ytbqjwhx@sina.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200023
- Recrutement
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Contact:
- Ranran Dai, Doctor
- Numéro de téléphone: 13918139360
- E-mail: drr11154@rjh.com.cn
-
-
Shanxi
-
Baoji, Shanxi, Chine, 721008
- Recrutement
- Baoji Central Hospital
-
Contact:
- Kai Chen, Master
- Numéro de téléphone: 18091698989
- E-mail: chenkailiyajie@163.com
-
Changzhi, Shanxi, Chine, 46000
- Recrutement
- Changzhi People's Hospital
-
Contact:
- Xianping Zhao, Bachelor
- Numéro de téléphone: 13453503966
- E-mail: ZXP13453503966@126.com
-
Xianyang, Shanxi, Chine, 712000
- Recrutement
- Yan'an University Xianyang Hospital
-
Contact:
- Jianhou Jia, Bachelor
- Numéro de téléphone: 13892007197
- E-mail: jjh20@126.com
-
Xi’an, Shanxi, Chine, 710100
- Recrutement
- Xi'an International Medical Center Hospital
-
Contact:
- Changgui Wu, Doctor
- Numéro de téléphone: 13892899669
- E-mail: wcg196211@163.com
-
Yangquan, Shanxi, Chine, 45000
- Recrutement
- Yangquan coal Industry(Group) General Hospital
-
Contact:
- Ruibin Guo, Bachelor
- Numéro de téléphone: 13935324120
- E-mail: grb8888@126.com
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610044
- Recrutement
- West China Hospital of Sichuan University
-
Contact:
- Weimin Li, Doctor
- Numéro de téléphone: 028-85423998
- E-mail: weimin003@163.com
-
Chengdu, Sichuan, Chine, 610000
- Recrutement
- The First Affiliated Hospital of Chengdu Medical College
-
Contact:
- Na Huang, Doctor
- Numéro de téléphone: 15928602354
- E-mail: 717308813@qq.com
-
Mianyang, Sichuan, Chine, 621000
- Recrutement
- Mianyang Hospital of Traditional Chinese Medicine
-
Contact:
- Ye Gao, Doctor
- Numéro de téléphone: 13881138014
- E-mail: gaoye1001@126.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300052
- Recrutement
- Tianjin Medical University General Hospital
-
Contact:
- Jie Cao, Master
- Numéro de téléphone: 13132088076
- E-mail: tjcaojie@sina.com
-
Tianjin, Tianjin Municipality, Chine, 300140
- Recrutement
- Tianjin 4th Center Hospital
-
Contact:
- Jingchun He, Master
- Numéro de téléphone: 13820132084
- E-mail: jingjunhe98@163.com
-
-
Xinjiang
-
Shihezi, Xinjiang, Chine, 832008
- Recrutement
- The First Affiliated Hospital of Shihezi University
-
Contact:
- Dong Liu, Master
- Numéro de téléphone: 13779702431
- E-mail: 13779702431@163.com
-
-
Zhejiang
-
Jinhua, Zhejiang, Chine, 321000
- Recrutement
- Jinhua municipal central hospital
-
Contact:
- Dan Zhu, Bachelor
- Numéro de téléphone: 13957962296
- E-mail: zhudan4252@sina.com
-
Jinhua, Zhejiang, Chine, 322100
- Recrutement
- Dongyang People's Hospital
-
Contact:
- Caimin Shu, Bachelor
- Numéro de téléphone: 13566722100
- E-mail: Dsycm2003@163.com
-
Wenzhou, Zhejiang, Chine, 325000
- Recrutement
- The Second Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Liqin Wu, Master
- Numéro de téléphone: 13587861043
- E-mail: happy-qin@163.com
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Cohort A:
- Subjects who have completed the TQC3721-III-01 clinical trial, demonstrated good medication compliance during the 24-week treatment period as required by the protocol (with no major protocol deviations related to medication compliance), and experienced no treatment-related SAEs.
- Sign the informed consent form and fully understand the trial content, procedures, and potential adverse reactions.
- Willing and able to comply with the trial arrangements and to use the nebulizer correctly.
- Subjects have no pregnancy plans from screening until at least 1 month after the last dose of the investigational drug and voluntarily adopt effective contraception measures.
- Patients with a clear clinical history and related symptoms of COPD (meeting the diagnostic criteria for COPD as outlined in the Chinese Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2021 Revised Edition)).
Cohort B:
- Sign the informed consent form prior to screening and fully understand the trial content, procedures, and potential adverse reactions.
- Willing and able to comply with the trial arrangements and to use the nebulizer correctly.
- Aged between 40 and 80 years (inclusive), both male and female subjects are eligible.
- Subjects have no pregnancy plans from screening until at least 1 month after the last dose of the investigational drug and voluntarily adopt effective contraception measures.
- Patients with a clear clinical history and related symptoms of COPD prior to screening (meeting the diagnostic criteria for COPD as outlined in the Chinese Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2021 Revised Edition)).
- At the screening visit (V1), post-bronchodilator (salbutamol 4 puffs) lung function shows an FEV1/FVC ratio <0.7, and 30% predicted value ≤ FEV1 < 80% predicted value.
- A modified Medical Research Council (mMRC) dyspnea scale score of ≥1 at screening (V1).
- Subjects on single or dual bronchodilator background therapy (with or without an Inhaled Corticosteroid component) must have been on stable treatment for at least 2 weeks prior to screening.
- Clinically stable COPD (no moderate or severe COPD exacerbations) within 4 weeks prior to the screening visit (Visit V1).
- Smoking history of ≥10 pack-years (pack-years: packs per day * years of smoking, e.g., 1 pack of 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years) OR a history of exposure to biomass fuels.
Exclusion Criteria:
Cohort A:
- History of life-threatening chronic obstructive pulmonary disease (COPD) (e.g., prior intensive care unit admission or requiring intubation).
- Presence of other clinically significant respiratory diseases, such as alpha-1 antitrypsin deficiency, active pulmonary infection, bronchiectasis, interstitial lung disease, pulmonary arterial hypertension, or asthma.
- Any other systemic disease deemed by the investigator to be clinically significant and not adequately controlled at present.
- History or current evidence of clinically significant cardiovascular or cerebrovascular disease, specifically including:
Myocardial infarction, unstable angina, or stroke within the past 6 months; Unstable or life-threatening arrhythmia requiring intervention within the past 3 months; New York Heart Association (NYHA) Functional Class III or IV heart failure.
- Poorly controlled hypertension despite medication (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg).
- Poorly controlled type 2 diabetes mellitus (e.g., fasting blood glucose >10 mmol/L).
- Planned surgery before the end of the study.
- History of malignancy in any organ system within the past 5 years (except for non-metastatic basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix, with complete remission for >5 years prior to screening).
- Clinically significant laboratory abnormalities at the screening visit (V1) as determined by the investigator, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 × upper limit of normal (ULN), alkaline phosphatase >2 × ULN, or total bilirubin >1.5 × ULN.
- Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.
- Any other condition considered by the investigator as unsuitable for participation in the study.
Cohort B:
- History of life-threatening COPD (e.g., prior intensive care unit admission or requiring intubation).
- Experienced a COPD exacerbation requiring systemic corticosteroids within 3 months prior to the screening visit (V1).
- One or more hospitalizations due to COPD exacerbation or pneumonia within 3 months prior to screening.
- Presence of other clinically significant respiratory diseases, as specified in Criterion A.2.
- Chest computed tomography (CT) scan showing clinically significant abnormalities not attributable to COPD and judged by the investigator to potentially affect trial evaluation or subject safety.
- Use of oral theophylline or its derivatives for COPD treatment within 1 week prior to the screening visit (V1).
- Prior treatment with TQC3721.
- Any other systemic disease deemed by the investigator to be clinically significant and not adequately controlled at present.
- History or current evidence of clinically significant cardiovascular or cerebrovascular disease, as specified in Criteria A.4.
- Poorly controlled hypertension, as specified in Criterion A.5.
- Poorly controlled type 2 diabetes mellitus, as specified in Criterion A.6.
- Major surgery (requiring general anesthesia) within 8 weeks prior to the screening visit (V1) with incomplete recovery, or planned surgery before the end of the study.
- Clinically significant laboratory abnormalities at screening, as specified in Criterion A.9.
- Requirement for long-term daily oxygen therapy (defined as cumulative use >12 hours per day).
- Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.
- Participation in any other investigational drug or medical device clinical trial within 4 weeks prior to screening, or within 5 half-lives of the previous investigational agent (whichever is longer).
- Any other condition considered by the investigator as unsuitable for participation in the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: TQC3721 Suspension for Inhalation (Twice a day)
Queue A: One TQC3721 suspension for inhalation (6mg/2ml), twice a day for 24 weeks. Queue B: One TQC3721 suspension for inhalation (6mg/2ml), twice a day for 12 weeks. |
TQC3721 suspension for inhalation is a Phosphodiesterase3/4 (PDE3/4) inhibitor. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse event rate
Délai: Queue A: Extended study period: Weeks 24-50; Queue B: At week 12 of treatment
|
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs). |
Queue A: Extended study period: Weeks 24-50; Queue B: At week 12 of treatment
|
|
Number of subjects with laboratory abnormalities
Délai: Queue A: Extended study period: Weeks 24-50; Queue B: At week 12 of treatment
|
Number of subjects with laboratory tests showing abnormal results |
Queue A: Extended study period: Weeks 24-50; Queue B: At week 12 of treatment
|
|
Change from baseline in trough Forced Expiratory Volume in 1 second (FEV₁)
Délai: At week 12 of treatment
|
Change in FEV₁ from baseline (pulmonary function at screening) at 12 weeks of treatment |
At week 12 of treatment
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Annualized rate of moderate or severe COPD acute exacerbations
Délai: Up to 48 weeks
|
Annualized rate of moderate or severe Obstructive Chronic Pulmonary Disease (COPD) acute exacerbations over 48 weeks of treatment (compared according to the treatment groups in the TQC3721-III-01 study). |
Up to 48 weeks
|
|
On-treatment time to first moderate or severe exacerbation
Délai: Up to 48 weeks
|
Time to first moderate or severe COPD exacerbation over the 48-week treatment period (To be compared according to the randomized treatment groups assigned in the TQC3721-III-01 study). |
Up to 48 weeks
|
|
Change from baseline in trough Forced Expiratory Volume in 1 second (FEV₁)
Délai: At weeks 32, 40, and 48 of treatment
|
Analysis of change from baseline in trough FEV₁ at weeks 32, 40, and 48 of treatment (Baseline is defined as the corresponding value from the TQC3721-III-01 study; comparisons will be performed according to the randomized treatment groups assigned in that study). |
At weeks 32, 40, and 48 of treatment
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladie chronique
- Attributs de la maladie
- Maladies des voies respiratoires
- Maladies pulmonaires
- Maladies pulmonaires obstructives
- Conditions pathologiques, signes et symptômes
- Maladie pulmonaire obstructive chronique
- Phénomènes physiologiques circulatoires et respiratoires
- Mécanique respiratoire
- Respiration
- Phénomènes physiologiques respiratoires
- Inhalation
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- TQC3721-III-02
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .